LINDSEY WEISS: Open Payments
NPI 1265930507 · CHEVY CHASE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,594 in 90 payments from 20 companies in 2025. Trend: 2023 $577 · 2024 $474 · 2025 $3,594
Food & beverage: $2,274Consulting: $960Travel & lodging: $360
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $1,766 |
| ABBVIE INC. | 10 | $213 |
| GENZYME CORPORATION | 9 | $212 |
| PFIZER INC. | 11 | $207 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $192 |
| Janssen Scientific Affairs, LLC | 3 | $182 |
| Janssen Biotech, Inc. | 7 | $152 |
| Ardelyx, Inc. | 3 | $142 |
| Lilly USA, LLC | 4 | $84 |
| Intercept Pharmaceuticals, Inc. | 3 | $76 |
Products named: ENTYVIO, TREMFYA, DUPIXENT, XIFAXAN, XELJANZ, IBSRELA, RINVOQ, OMVOH.
Industry payments across MD — which companies pay providers there.
